CSIMarket
 


Eli Lilly And Company  (LLY)
Other Ticker:  
 
 

LLY's Revenue Growth by Quarter and Year

Eli Lilly And's Revenue results by quarter and year




LLY Revenue (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
IV Quarter December - 7,440.00 6,114.00 7,135.80
III Quarter September - 5,740.60 5,476.60 6,061.90
II Quarter June - 5,499.40 5,636.70 6,355.20
I Quarter March 6,805.60 5,859.80 5,092.20 5,700.00
FY   6,805.60 24,539.80 22,319.50 25,252.90



LLY Revenue first quarter 2021 Y/Y Growth Comment
Eli Lilly And Company achieved in the first quarter, above Company average Revenue increase of 16.14% year on year, to $ 6,805.60 millions.

Looking into first quarter results within Major Pharmaceutical Preparations industry 2 other companies have achieved higher Revenue growth. While Eli Lilly And Company' s Revenue growth of 16.14% ranks overall at the positon no. 261 in the first quarter.




LLY Revenue ( Y/Y Growth %) 2021
2020 2019 2018
IV Quarter December - 21.69 % -14.32 % 15.83 %
III Quarter September - 4.82 % -9.66 % 7.14 %
II Quarter June - -2.44 % -11.31 % 9.12 %
I Quarter March 16.14 % 15.07 % -10.66 % 9.02 %
FY   - 9.95 % -11.62 % 10.41 %

Financial Statements
Eli Lilly And's first quarter 2021 Revenue $ 6,805.60 millions LLY's Income Statement
Eli Lilly And's first quarter 2020 Revenue $ 5,859.80 millions Quarterly LLY's Income Statement
New: More LLY's historic Revenue Growth >>


LLY Revenue (Quarter on Quarter Growth %)

2021
2020 2019 2018
IV Quarter December - 29.6 % 11.64 % 17.72 %
III Quarter September - 4.39 % -2.84 % -4.62 %
II Quarter June - -6.15 % 10.69 % 11.49 %
I Quarter March -8.53 % -4.16 % -28.64 % -7.48 %
FY (Year on Year)   - 9.95 % -11.62 % 10.41 %




Revenue first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #3
Healthcare Sector #21
Overall #261

Revenue Y/Y Growth Statistics
High Average Low
11.83 % 1.19 % -4.48 %
(Sep. 30, 2015)   (June 30. 2014)
Revenue first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #3
Healthcare Sector #21
Overall #261
Revenue Y/Y Growth Statistics
High Average Low
11.83 % 1.19 % -4.48 %
(Sep. 30, 2015)   (June 30. 2014)

Revenue by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Eli Lilly And's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
29.6 % 1.36 % -28.64 %
 


LLY's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2021 Eli Lilly And Company realized drop in Revenue sequentially by -8.53% to $ 6,805.60 millions, from $ 7,440.00 millions declared in the previous quarter.

It's not huge problem, as Revenue frequently tend to dip in the I. Quarter.

Within Major Pharmaceutical Preparations industry 9 other companies have achieved higher Revenue quarter on quarter growth. While Eli Lilly And's Revenue growth quarter on quarter, overall rank is 577.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #10
Healthcare Sector #49
Overall #577
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #10
Healthcare Sector #49
Overall #577
Revenue Q/Q Growth Statistics
High Average Low
29.6 % 1.36 % -28.64 %
 


LLY's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2021 Eli Lilly And Company disclosed drop in Revenue sequentially by -8.53% to $ 6,805.60 millions, from $ 7,440.00 millions released in the previous quarter.

When you look into present slump in the quarter, you suppose to take into consideration, that commonly I. Quarter Revenue appear to be weaker then in the preciding period, Emily  White, Major Pharmaceutical Preparations industry observer situated in Birmingham added.

Within Major Pharmaceutical Preparations industry 9 other companies have achieved higher Revenue quarter on quarter growth. While Eli Lilly And's Revenue growth quarter on quarter, overall rank is 577.


Eli Lilly And's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2021)
12 Months Ending
(Dec 31 2020)
12 Months Ending
(Sep 30 2020)
12 Months Ending
(Jun 30 2020)
12 Months Ending
(Mar 31 2020)
Cumulative Revenue 12 Months Ending $ 25,485.60 $ 24,539.80 $ 23,213.80 $ 22,949.80 $ 23,087.10
Y / Y Revenue Growth (TTM) 10.39 % 9.95 % -0.55 % -4.08 % -6.32 %
Year on Year Revenue Growth Overall Ranking # 195 # 1021 # 1706 # 1976 # 2389
Seqeuential Revenue Change (TTM) 3.85 % 5.71 % 1.15 % -0.59 % 3.44 %
Seq. Revenue Growth (TTM) Overall Ranking # 261 # 227 # 1610 # 513 # 843




Cumulative Revenue growth Comment
Eli Lilly And saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 10.39% year on year, to $ 25,486 millions if the fiscal year would have ended in Mar 31 2021.
Eli Lilly And's trailing twelve months Revenue growth was higher than company's average 4.02% and higher than 9.95% growth in Dec 31 2020.
But from twelve months ended Dec 31 2020 rise was slower at 3.85 % from $24539.8 millions reported in twelve months ending a quarter Dec 31 2020.
Yet it was evidence of strength, while the average Q/Q TTM Revenue advancement stands at 1.19%.
The progress is even stronger from the previous reporting period clinched at 3.85 % rise from $24539.8 millions in twelve months ending a quarter Dec 31 2020.

Within the Healthcare sector 21 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 195, from total ranking in previous quarter at 1021.

Revenue TTM Q/Q Growth Statistics
High Average Low
11.83 %
1.19 %
-4.48 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 3
Healthcare Sector # 22
Overall # 195

Revenue TTM Y/Y Growth Statistics
High Average Low
18.75 %
4.02 %
-15.13 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 3
Sector # 21
S&P 500 # 261
Cumulative Revenue growth Comment
Eli Lilly And saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 10.39% year on year, to $ 25,486 millions if the fiscal year would have ended in Mar 31 2021.
Eli Lilly And's trailing twelve months Revenue growth was higher than company's average 4.02% and higher than 9.95% growth in Dec 31 2020.
But sequential increase was less at 3.85 % from $24539.8 millions achieved in the period from Dec 31 2020 to Mar 31 2020.
Yet it was evidence of strength, while the typical sequential growth lays at 1.19%.
The progress was much stronger from the previous reporting period clinched at 3.85 % jump from $24539.8 millions in twelve months ending a quarter before.

Within the Healthcare sector 21 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 195, from total ranking in previous quarter at 1021.

Revenue TTM Q/Q Growth Statistics
High Average Low
11.83 %
1.19 %
-4.48 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 3
Healthcare Sector # 22
Overall # 195

Revenue TTM Y/Y Growth Statistics
High Average Low
18.75 %
4.02 %
-15.13 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 3
Sector # 21
S&P 500 # 261




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
LLY's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for LLY's Competitors
Revenue Growth for Eli Lilly And's Suppliers
Revenue Growth for LLY's Customers

You may also want to know
LLY's Annual Growth Rates LLY's Profitability Ratios LLY's Asset Turnover Ratio LLY's Dividend Growth
LLY's Roe LLY's Valuation Ratios LLY's Financial Strength Ratios LLY's Dividend Payout Ratio
LLY's Roa LLY's Inventory Turnover Ratio LLY's Growth Rates LLY's Dividend Comparisons



Companies with similar Revenue drop for the quarter ending Mar 31 2021 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2021
Karyopharm Therapeutics Inc 28.24%$ 28.239 millions
Axogen inc 27.93%$ 27.930 millions
Alpha Pro Tech Ltd27.58%$ 27.581 millions
Insulet Corporation27.42%$ 27.424 millions
Antares Pharma Inc 27.22%$ 27.220 millions
Chembio Diagnostics Inc 27.18%$ 27.185 millions
Bio rad Laboratories Inc 27.14%$ 27.141 millions
Albireo Pharma inc 26.92%$ 26.921 millions
Gw Pharmaceuticals Plc26.39%$ 26.388 millions
Aclaris Therapeutics Inc 26.30%$ 26.297 millions
Bio techne Corp25.10%$ 25.104 millions
Dexcom Inc 24.66%$ 24.661 millions
Idexx Laboratories Inc24.17%$ 24.168 millions
Establishment Labs Holdings Inc 23.92%$ 23.917 millions
Iqvia Holdings Inc 23.78%$ 23.784 millions
Cerus Corporation23.39%$ 23.393 millions
Macrogenics Inc 23.38%$ 23.381 millions
Penumbra Inc23.21%$ 23.211 millions
Glaukos Corp22.83%$ 22.828 millions
Zoetis Inc 21.97%$ 21.969 millions
Cytosorbents Corporation21.72%$ 21.724 millions
Amphastar Pharmaceuticals Inc 21.65%$ 21.647 millions
Si bone inc 21.53%$ 21.527 millions
Henry Schein Inc 20.42%$ 20.425 millions
Viemed Healthcare Inc 19.36%$ 19.365 millions
Pra Health Sciences Inc 19.15%$ 19.148 millions
Fluidigm Corp18.75%$ 18.746 millions
Acadia Pharmaceuticals Inc 18.30%$ 18.304 millions
Immunogen inc 18.21%$ 18.206 millions
Avantor Inc 17.55%$ 17.551 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

AUD's Profile

Stock Price

AUD's Financials

Business Description

Fundamentals

Charts & Quotes

AUD's News

Suppliers

AUD's Competitors

Customers & Markets

Economic Indicators

AUD's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071